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ABSTRACT
Objective Patients with rheumatoid arthritis (RA) are
at increased cardiovascular risk. Recent studies suggest
that high-density lipoprotein (HDL) may lose its
protective vascular phenotype in inﬂammatory
conditions. However, the effects of common anti-
inﬂammatory treatments on HDL function are not yet
known.
Methods We compared the function of HDL in 18
patients with RA and 18 matched healthy controls.
Subsequently, patients were randomised to (methotrexate
+inﬂiximab (M+I) (5 mg/kg)) or methotrexate+placebo
(M+P) infusions for 54 weeks. At week 54 and
thereafter, all patients received inﬂiximab therapy until
completion of the trial (110 weeks), enabling assessment
of the impact of 1 year of inﬂiximab therapy in all
patients. HDL functional properties were assessed at
baseline, 54 weeks and 110 weeks by measuring the
impact on endothelial nitric oxide (NO) bioavailability
and superoxide production (SO), paraoxonase activity
(PON-1) and cholesterol efﬂux.
Results All HDL vascular assays were impaired in
patients compared with controls. After 54 weeks, NO in
response to HDL was signiﬁcantly greater in patients
who received M+I compared with those who received
M+P. Endothelial SO in response to HDL was reduced in
both groups, but PON-1 and cholesterol efﬂux remained
unchanged. All vascular measures improved compared
with baseline after ≥1 inﬂiximab therapy in the analysis
at 110 weeks. No signiﬁcant trend was noted for
cholesterol efﬂux.
Conclusions HDL function can be improved with anti-
inﬂammatory treatment in patients with RA. The M+I
combination was superior to the M+P alone, suggesting
that the tumour necrosis factor-α pathway may have a
role in HDL vascular properties.
INTRODUCTION
Cardiovascular (CV) disease remains the leading
cause of morbidity and mortality in patients with
rheumatoid arthritis (RA).1 Conventional risk
factors do not account fully for this, and increased
levels of inﬂammation associated with RA may be
an important determinant of CV outcomes.2 In a
study of 651 patients, an elevated inﬂammatory
state was associated with an increased CV event rate
but a paradoxical reduction in circulating lipid
levels.3 This suggests that the relationship between
lipid levels and increased CV disease is altered in
RA and may be explained, at least in part, by
qualitative changes to lipoproteins as a result of the
inﬂammatory milieu.
High-density lipoprotein (HDL) has been sug-
gested to exert anti-atherosclerotic effects via
reverse cholesterol transport and activation of pro-
tective endothelial pathways. In conditions such as
RA however, HDL has been shown to acquire
pro-inﬂammatory and pro-thrombotic phenotype
that can promote atherogenesis and potentially
increase CV risk.4 5 A previous study from our
group demonstrated that the beneﬁcial function of
HDL can be restored after resolution of acute
inﬂammatory stimulus, suggesting that the modiﬁ-
cation of systemic inﬂammation offers potential for
CV risk reduction.6
In our current study, we examined the inﬂuence
of standard (methotrexate (MTX)) and novel anti-
inﬂammatory treatments (inﬂiximab) on HDL func-
tion in patients with RA in a randomised controlled
trial over 1 year. We also assessed the long-term
effect of inﬂiximab on HDL function and CV and
RA risk factors. Our ﬁndings support the concept
that HDL dysfunction can be improved by anti-
inﬂammatory drugs that are widely used for RA
therapy and this may confer CV beneﬁt.
METHODS
Study population and protocol
RA population
We studied 18 patients with early erosive RA who
were required to have (i) a diagnosis of RA accord-
ing to the American College of Rheumatology
1987 criteria, (ii) symptoms for 6 months—3 years,
(iii) a minimum of two swollen metacarpophalan-
geal (MCP) joints despite treatment with MTX and
(iv) seropositivity for IgM rheumatoid factor. In
addition, eligible patients were required to have
either (i) erosion of ≥1 MCP joint as demonstrated
on plain radiography or as a cortical break with
irregular margins (or contour) on greyscale ultra-
sound in both the longitudinal and transverse scan-
ning planes or (ii) erosions of ≥2 MCP joints
(cortical breaks with irregular margins/contour on
greyscale ultrasound in either the transverse or the
longitudinal plane associated with a strong vascular
signal in power Doppler mode at the site of the
cortical break).7
All patients received oral MTX for greater than
or equal to at least 8 weeks, at a minimum stable
dosage of 12.5 mg/week but not exceeding
17.5 mg/week. Patients being treated with oral
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corticosteroids must have been receiving a stable dosage (10 mg
prednisolone per day) for 4 weeks.
Study 1: case–control study
Vascular properties of HDL from 18 patients with RA were
compared with 18 healthy control subjects. Healthy controls
had no CV risk factors by history, clinical examination and
laboratory tests, and were matched to patients with RA for age
and gender.
Study 2: randomised clinical trial (double-blind phase)—
secondary analysis
All physicians, patients, nurses and other non-clinical members
of the study team were blinded for the ﬁrst year of the study.
Eighteen patients with RA were randomised into one of two
treatment groups by a pharmacist who did not participate in the
screening visit. Eleven patients received infusions of inﬂiximab at
5 mg/kg and seven received placebo (normal saline) infusions at
weeks 0, 2 and 6, and then every 8 weeks through week 46. At
the end of the ﬁrst year, all patients were maintained a single-
blinded study for a further year. Patients in the methotrexate
+inﬂiximab (M+I ) group received inﬂiximab infusions at weeks
54, 56, 62 and thereafter every 8 weeks. Those in the M+I
group received a placebo infusion at week 56 in order to main-
tain blinding and received inﬂiximab infusions every 8 weeks
until the end of the study (110 weeks) (see online supplementary
appendix ﬁgure 1). As a result, all patients received a minimum
of 1 year of inﬂiximab in the two phases of the study.
Baseline dosages of MTX or corticosteroid were maintained
during the ﬁrst 18 weeks of the study. After week 18, if any
patient failed to achieve a 50% reduction from baseline in the
number of swollen hand and wrist joints, the weekly dose of
MTX was increased by 2.5 mg once every 4 weeks until a 50%
reduction from baseline in the number of swollen hand and
wrist joints was achieved, until the dosage of oral MTX reached
25 mg/week or until the dose escalation was limited by toxicity.
Thereafter, irrespective of their response status, patients contin-
ued to receive the maximum tolerated MTX dosage until the
end of the study. The study was approved by Riverside Research
Ethics Committee, and all patients provided informed consent.
Clinical monitoring of the study was performed independently
(Centocor, Malvern, Pennsylvania, USA).
Laboratory assays
Anthropometric and biochemical measurements
Anthropometric measurements were made and body mass index
(BMI (kg/m2)) was calculated from weight and height. Blood
pressure was measured in triplicate (HEM-705CP, Omron), and
the average of the readings was calculated. Blood was drawn and
processed after an overnight fast, and serum and plasma samples
were stored at −70°C for subsequent analysis. Full blood count,
lipid and glucose level measurements were made with standard
biochemistry assays and C reactive protein (CRP) was measured
with an immunoturbidimetric, high-sensitivity assay (Tina-quant
assay performed on a Cobas Integra analyzer, Roche Diagnostics).
HDL measurements
Measurements of HDL function were carried out at baseline,
54 weeks and 110 weeks in patients with RA. Baseline measure-
ments were compared with those from healthy controls.
HDL isolation
HDL was isolated by sequential ultracentrifugation (d=1.063–
1.21 g/mL) using solid potassium bromide for density
adjustment.8 All functional assays of HDL were carried out
within two weeks of isolation by a blinded investigator in
duplicate.
Endothelial nitric oxide bioavailability
The effect of HDL (50 μg/mL: 60 min, 37°C) on endothelial
nitric oxide (NO) bioavailability (bovine aortic endothelial cells
(BAECs): passage 4–7; Lonza Bioscience) was measured using a
ﬂuorescent indicator. BAECs were incubated with
4,5-diaminoﬂuorescein diacetate (DAF-2; 1Um; Cayman
Chemical), and triazoloﬂuorescein ﬂuorescence was measured
using an excitation wavelength of 485 nm.9
Endothelial superoxide production
The effect of HDL on endothelial cell superoxide production
(SO) was measured in unstimulated and tumour necrosis factor-α
(TNF-α)-stimulated (5 ng/mL, R&D Systems) human aortic
endothelial cells (HAECs) by erythrocyte sedimentation rate
(ESR) spectroscopy. HAECs were incubated with HDL from
patients and controls (50 μg/mL, 60 min, 37°C), with or without
TNF-α and resuspended in Krebs-Hepes buffer (pH 7.4;
Noxygen) containing diethyldithiocarbamic acid sodium salt
(5 μM, Noxygen) and deferoxamine methanesulfonate salt
(25 μM, Noxygen). ESR spectra were recorded after addition of
the spin probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetra-
methylpyrrolidine (CMH; Noxygen; ﬁnal concentration
200 μM) using a Bruker e-scan spectrometer (Bruker Biospin).
The ESR instrumental settings were centre ﬁeld (B0) 3495 G;
ﬁeld sweep width 10 G; microwave frequency 9.75 GHz; micro-
wave power 19.91 mW; magnetic ﬁeld modulation frequency
86.00 kHz; modulation amplitude 2.60 G; conversion time
10.24 ms; and number of x-scans 1020.9
Cholesterol efﬂux capacity
HDL for measurements of efﬂux capacity was extracted from
serum by ApoB depletion. Whole serum was incubated for
20 min with a 20% polyethylene glycol (PEG) solution (20%
PEG 8000 (sigma P2139) in 200 mM glycine (sigma G8898,
pH=10)). Samples were centrifuged at 1900 g, and the super-
natant was collected and stored at 4°C. J774 cells were radi-
olabeled for 24 hours in a medium containing 2 μCi of
[3H]-cholesterol per microlitre. Addition of 0.3 mM 8--
(4-chlorophenylthio)-cyclic AMP for 6 hours upregulated
expression of ABCA1. An efﬂux medium containing 2.8%
apolipoprotein B-depleted serum from each individual was
added for 4 hours. To prevent cholesterol esteriﬁcation during
labelling, equilibration and ﬂux, 2 μg/mL of CP113,818, a
acyl-coenzyme A:cholesterol acyltransferase inhibitor was
added to all mediums. Efﬂux capacity was quantiﬁed using
liquid scintillation to measure radioactive cholesterol efﬂuxed
from the cells (medium+intracellular lipids). All assays were
performed in duplicate and the ﬁnal average value normalised
against a baseline control for statistical analyses between time
points.10
Paraoxonase-1 activity
Serum paraoxonase activities were measured by ultraviolet spec-
trophotometry in a 96-well plate format using paraoxon
(Sigma-Aldrich, St Louis, Missouri, USA). Brieﬂy, 50 μg/mL HDL
was diluted in a reaction mixture containing 10 mM Tris hydro-
chloride (pH 8.0), 1 M sodium chloride and 2 mM calcium
chloride. At 24°C, 1.5 mM paraoxon was added to initiate the
reaction, and the increase in absorbance at 405 nm was recorded
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over 30 min. An extinction coefﬁcient (at 405 nm) of 17 000
M−1 • cm−1 was used to calculate units of paraoxonase-1
(PON-1).11
Statistics
HDL studies were powered for a 1:1 randomised controlled
trial on the basis of NO bioavailability using paired assessments
in 35 healthy controls (mean=0.98, SD =0.13, and intraclass
correlation 0.91).12 From this power calculation, a total of
seven patients per group was required (power=80% and
α=0.05) to detect a 5% difference in the primary outcome (NO
bioavailability). Normal distribution was assessed using the
Shapiro-Wilk test. All measures are reported as mean (SD) or
median (IQR) for those not normally distributed. Baseline com-
parisons were performed using an independent t-test or
Mann-Whitney U test if data was non-normally distributed.
Post hoc multivariate analysis of variance (ANOVA) modelling
was performed to evaluate the effects of treatment with inﬂixi-
mab (vs placebo) and duration of treatment on HDL function,
CV and clinical markers at 54 weeks. A repeated-measures
ANOVA, with time point comparisons using Bonferroni-
corrected t-tests, was performed to determine differences in
HDL function, CV and clinical markers in patients who received
2 years inﬂiximab treatment. The Greenhouse-Geisser correc-
tion for the F test was used to adjust the degrees of freedom for
deviation from sphericity. Analysis was performed using
GraphPad Prism analysis software. A two-sided p value of
<0.05 was considered to indicate statistical signiﬁcance. An add-
itional multilevel logistic regression analysis was conducted in R
to conﬁrm our results (see online supplementary appendix 2).
We ﬁt multilevel logistic regression models for measure of HDL
function using the lme4 package (http://cran.r-project.org/web/
packages/lme4/index.html) in the R statistical language (http://
www.r-project.org/). All coefﬁcients were taken as random
effects.
RESULTS
Cross-sectional study: comparison between patients with RA
and controls
The patients and controls were well matched for age, gender
and BMI (table 1). Patients with RA had signiﬁcantly lower
HDL-cholesterol (HDL-c) levels (p=0.01), but increased trigly-
ceride levels (p<0.01). Total cholesterol and low-density lipo-
protein (LDL)-c were similar between the groups (table 1).
Patients with RA had signiﬁcantly higher CRP levels (p<0.01)
and lower blood glucose levels compared with controls
(p=0.01).
HDL, which was isolated from patients with RA, showed
reduced NO bioavailability and increased SO production
(p<0.01 for both) in cultured endothelial cells compared with
controls. Paraoxonase activity was also impaired in patients with
RA (p=0.03) (ﬁgure 1).
Double-blind randomised control study: lipid levels and HDL
functional properties after 1 year of treatment
Both treatment groups were balanced for CV risk factors, RA
disease activity and HDL function at baseline (table 2).
An increase in total cholesterol levels was observed in the
Table 1 Baseline characteristics in rheumatoid arthritis and
healthy participants
Control
n=18
Rheumatoid
arthritis
n=18 p Value
Demographics
Age (years) 55.61 (6.37) 58.56 (11.05) 0.20
Gender (proportion
female)
10/18 12/18 0.48 (χ2 test)
Cardiovascular risk
BMI (kg/m2) 26.27 (2.29) 24.42 (4.71) 0.14
Total cholesterol
(mmol/L)
4.93 (0.66) 5.00 (1.43) 0.79
HDL (mmol/L) 1.35 (0.44) 1.02 (0.19) 0.01
LDL (mmol/L) 2.89 (0.88) 3.01 (1.19) 0.74
Triglyceride
(mmol/L)
1.13 (0.36) 2.19 (0.96) <0.01
Glucose (mg/dL) 4.95 [4.70–5.82] 4.49 [3.46–4.94] 0.01
Inflammation
CRP (mg/L) 1.00 [1.00–1.00] 22.74 [13.76–40.78] <0.01
Values expressed as mean (SD) and median [IQR] for non-normally distributed data.
Comparisons between rheumatoid patients and healthy controls were performed
using the independent t-test. Categorical variables were compared using Fisher’s
exact χ2 test. Comparisons for non-parametric measurements were performed using
Mann-Whitney test.
BMI, body mass index; CRP, C reactive protein; HDL, high-density lipoprotein; LDL,
low-density lipoprotein.
Figure 1 Comparison of the functional properties of high-density
lipoprotein between patients with rheumatoid arthritis (RA) and healthy
controls. (A) Nitric oxide bioavailability. (B) Superoxide production. (C)
Paraoxonase-1 (PON-1) activity. Individual data points for each patients
(n=18 in each group). Error bars represent mean and SEM.
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inﬂiximab arm at 54 weeks (p=0.04) and was primarily driven
by an increase of HDL-c (p=0.02). M+P treatment did not
alter lipid proﬁle. CRP was signiﬁcantly reduced with inﬂixi-
mab treatment compared with MTX alone (p=0.03), which
did not demonstrate a signiﬁcant change at 54 weeks. Clinical
and laboratory measures of RA were improved with M+I
therapy, but no changes were detected in the M+P arm
(table 3).
Table 2 Baseline characteristics of patients with RA entering randomised trial
Placebo
n=7
Infliximab
n=11 p Value
Demographics
Age (years) 55.86 (15.89) 61.30 (11.05) 0.42
Gender (proportion female) 4/7 8/11 0.31 (χ2 test)
Cardiovascular risk
BMI (kg/m2) 25.88 (0.55) 24.98 (5.11) 0.73
Total cholesterol (mmol/L) 5.05(1.42) 5.01 (1.5) 0.96
HDL-c (mmol/L) 1.10 (0.22) 0.97 (0.17) 0.20
LDL-c (mmol/L) 3.20 (0.95) 2.90 (1.34) 0.62
Triglyceride (mmol/L) 1.67 (1.00) 2.52 (0.81) 0.63
Glucose (mg/dL) 4.60 (0.70) 4.75 (1.24) 0.59
Systolic BP (mm Hg) 140.70 (7.27) 132.5 (4.67) 0.33
Diastolic BP (mm Hg) 75.71 (3.96) 76.00 (3.70) 0.96
HDL function
Nitric oxide bioavailability (% buffer-treated cells) 81.81 (3.97) 84.23 (6.23) 0.37
Superoxide production (nmol/O2-/100 000 cells) 4.37 (1.71) 3.90 (1.66) 0.56
Paraoxonase-1 activity (μmol p-nitrophenol/L/serum/min) 137.52 (1.71) 148.24 (14.49) 0.09
Efflux capacity (%) 12.25 (2.04) 13.52 (1.26) 0.31
RA disease activity
CRP (mg/L) 37.65 [19.48–64.31] 26.83 [14.37–37.33] 0.22
ESR (mm/hours) 30.00 [22.00–76.00] 25.00 [14.00–50.50] 0.36
DAS28—CRP score 6.08 (0.71) 5.17 (1.13) 0.09
DAS28—ESR score 5.59 (0.85) 4.68 (1.56) 0.15
Values expressed as mean (SD) and median [IQR] for non-normally distributed data. Comparisons between groups were performed using the independent t-test. Categorical variables
were compared using Fisher’s exact χ2 test. Comparisons for non-parametric measurements were performed using Mann-Whitney test.
APO4, Apolipoprotein A; BMI, body mass index; BP, blood pressure; CRP, C reactive protein; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation rate; HDL-c, high-density
lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; RA, rheumatoid arthritis.
Table 3 Clinical characteristics and HDL function at 1 year
MTX+placebo MTX+infliximab
Baseline One year p Value Baseline One year p Value
Cardiovascular risk
Total cholesterol (mmol/L) 5.05 (1.42) 5.13 (1.55) 0.84 5.01 (1.5) 6.23 (1.63) 0.04
HDL-c (mmol/L) 1.10 (0.22) 1.10 (0.42) 0.14 1.02 [0.93–1.09] 1.33 [1.26–1.50] 0.02
LDL-c (mmol/L) 3.20 (0.95) 3.18 (1.23) 0.96 2.90 (1.34) 3.65 (1.22) 0.07
Triglyceride (mmol/L) 1.35 [1.07–1.62] 1.26 [1.12–1.43] 0.20 2.52 (0.81) 2.48 (0.92) 0.91
Glucose (mg/dL) 4.59 [4.28–4.76] 4.40 [4.04–5.12] 0.61 4.75 (1.24) 4.99 (0.95) 0.15
HDL function
Nitric oxide bioavailability
(% buffer-treated cells)
81.81 (3.97) 82.72 (3.43) 0.67 84.23 (6.23) 89.08 (9.31) 0.02
Superoxide production
(nmol/O2-/100 000 cells)
4.37 (1.71) 3.63 (1.67) 0.03 3.90 (1.66) 2.98 (1.47) 0.01
Paraoxonase-1 activity
(μmol p-nitrophenol/L/serum/min)
137.52 (6.41) 153.58 (17.88) 0.07 148.24 (14.49) 155.15 (14.86) 0.07
Efflux capacity (%) 12.25 (2.04) 13.25 (2.52) 0.26 13.52 (1.26) 14.01 (3.23) 0.72
RA disease activity
CRP (mg/L) 37.65 [19.48–64.31] 26.00 [13.85–36.83] 0.09 26.83 [14.37–37.33] 2.34 [0.00–6.34] 0.03
ESR (mm/hours) 30.00 [22.00–76.00] 27.50 [16.00–38.00] 0.69 25.00 [14.00–50.50] 20.50 [11.00–30.00] 0.61
DAS28—CRP score 6.08 (0.71) 5.04 (0.85) 0.14 5.17 (1.13) 3.53 (1.06) <0.01
DAS28—ESR score 5.59 (0.85) 4.43 (1.74) 0.08 4.68 (1.56) 2.25 (0.83) <0.01
Values expressed as mean (SD) and median [IQR] for non-normally distributed data. Comparisons between groups were performed using a paired t-test. Comparisons for non-parametric
measurements were performed using Wilcoxon signed-rank test.
CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; MTX, methotrexate; RA, rheumatoid
arthritis.
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SO production was reduced from baseline following both
M+P and M+I treatments (p=0.03 and 0.01). NO bioavailabil-
ity was improved (p=0.02) with M+I therapy, but no effect
was noted in the M+P patients. PON-1 activity increased in a
non-signiﬁcant manner in both groups, but cholesterol efﬂux
capacity remained unchanged (ﬁgure 2). Between-treatment
comparisons at 54 weeks did not demonstrate beneﬁt of M+I
treatment over M+P treatment for any measure of HDL func-
tion. These results were conﬁrmed in a multilevel logistic regres-
sion model (see online supplementary appendix 2).
Single-blinded study
In grouped analysis of the 18 patients who received 54 weeks of
M+I treatment, NO bioavailability increased compared with
baseline (p<0.01). Furthermore, a reduction in SO (p<0.01)
and an increase of PON-1 (both p=0.03) was seen (ﬁgure 3).
No change in cholesterol efﬂux capacity was noted. Lipid levels
were increased and inﬂammatory and RA disease activity scores
were signiﬁcantly reduced (data not shown).
Two years inﬂiximab treatment
Eleven patients received inﬂiximab therapy for 110 weeks. Total
cholesterol (p=0.08) and LDL-c (p=0.09) showed a non-
signiﬁcant increase at 110 weeks, but there was a signiﬁcant
increase in HDL-c (p=0.01). CRP and RA disease activity scores
were both signiﬁcantly reduced. No changes were noted for
cholesterol efﬂux (ﬁgure 4).
Repeated-measures ANOVA demonstrated a signiﬁcant
increase in NO bioavailability (p=0.01) and signiﬁcant reduc-
tions in SO production (p=0.02) and PON-1 (p=0.01). There
was no further improvement in HDL function between patients
who had received 54 weeks of M+I treatment compared with
110 weeks of M+I treatment. All measures of HDL function
remained impaired compared with the healthy controls (data
not shown).
DISCUSSION
This study shows that anti-inﬂammatory treatments can improve
the antioxidant and endothelial protective properties of HDL in
Figure 2 Comparison of (A) nitric oxide (NO) bioavailability, (B) superoxide production, (C) paraoxonase-1 (PON-1) activity and (D) cholesterol
efﬂux during placebo controlled phase of trial. Box and whisker plot represents mean and 95% CIs.
Figure 3 Trends in high-density lipoprotein function following 1 year
inﬂiximab treatment for (A) nitric oxide (NO) bioavailability, (B)
superoxide production and (C) paraoxonase-1 (PON-1) activity.
Individual data points for each patient (n=18). Error bars represent
mean and SEM.
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patients with erosive RA. These effects were not accompanied
by changes in cholesterol efﬂux and tracked improvements in
RA disease activity. Treatment with inﬂiximab in addition to
MTX for 2 years showed a beneﬁt for a broad range of HDL
functional properties including NO bioavailability, SO produc-
tion and PON-1 activity. These ﬁndings suggest that there is a
role for anti-inﬂammatory treatments, particularly those target-
ing the TNF-α pathway, for improving not only RA disease
activity but also potentially CV risk factors in patients with RA.
The threefold increased risk of CV disease in patients with
RA is not accounted for by traditional risk factors and is related
to increased levels of inﬂammation.2 This inﬂuences a range of
CV risk factors and causes quantitative and qualitative changes
to lipoproteins.13 Substantial evidence has now accumulated,
suggesting that inﬂammation can convert the normally protect-
ive HDL into a ‘particle with adverse effects on endothelial
function’.4 14
We showed that HDL has several dysfunctional properties in
patients with RA, which may contribute to their increased CV
risk. Our ﬁndings are in agreement with previous evidence
describing a pro-inﬂammatory HDL particle with reduced
PON-1 activity.15 We have now demonstrated an impairment of
the beneﬁcial effects of HDL on endothelium with a marked
decrease in the stimulation of endothelial NO and increase in SO
production compared with healthy controls. Diminished produc-
tion of NO may reﬂect endothelial dysfunction, an early step in
atherogenesis, and represents a novel pathway by which HDL
dysfunction can promote arterial disease in patients with RA.
We evaluated the potential for HDL function to be restored
following treatment with RA anti-inﬂammatory therapies. MTX
is commonly used as a ﬁrst-line treatment in early RA.
Observational studies have demonstrated reduced rates of myo-
cardial infarction and stroke with MTX therapy and the
ongoing CIRT trial is evaluating the drug in secondary CV pre-
vention.16 17 Its exact anti-inﬂammatory mechanisms remain
uncertain, although it has been shown to mediate increased
extracellular accumulation of adenosine around connective
tissue and reduce levels of CRP and interleukin-6.17 Biological
inhibition of TNF-α with inﬂiximab in addition to MTX is a
more effective approach for reducing RA disease activity. TNF-α
is a proximal cytokine and its blockade has well-established anti-
inﬂammatory actions and effects on lipid metabolism.18 At
54 weeks, NO bioavailability was signiﬁcantly improved in
patients who received inﬂiximab, but not with MTX. Inﬂiximab
has previously been associated with increased AKT/eNOS phos-
phorylation and improved endothelial function.19 20 Our study
provides a novel mechanism by which inﬂiximab can improve
endothelial function and contribute to vascular protection by
TNF-α inhibition.
After 1 year of our double-blinded randomised trial, SO pro-
duction was signiﬁcantly reduced in both arms. MTX is known
to inhibit several inﬂammatory and oxidative stress mediators,
associated with increased lipid peroxidation.21 Oxidative modiﬁ-
cation of the HDL particle alters its protective phenotype.22
Combination therapy with inﬂiximab caused an additional
reduction of SO production compared with MTX alone.
Previous studies of inﬂiximab in humans suggest that TNF-α
inhibition protects against oxidative DNA damage and lipid per-
oxidation, and this may explain its additional efﬁcacy in redu-
cing SO production.23 Despite a trend towards an increased
beneﬁt of inﬂiximab therapy at 1 year, between-treatment com-
parisons did not reach statistical signiﬁcance.
Assay of PON-1 provided an additional measure of the anti-
oxidative function of HDL but no signiﬁcant difference was
found in the double-blinded randomised study in either arm at
1 year possibly due to the small sample size. However, PON-1
activity was improved in the single-blinded study at 1 and
2 years treatment of inﬂiximab. While the effect of MTX on
PON-1 activity has not previously been reported, inﬂiximab is
known to improve PON-1 activity through the reduction of
Figure 4 Comparison of (A) nitric oxide (NO) bioavailability, (B) superoxide production, (C) paraoxonase-1 (PON-1) activity and (D) cholesterol
efﬂux after 2 years treatment with inﬂiximab. Individual data points representative for each patient (n=11). n.s., not signiﬁcant.
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lipid peroxidation including myeloperoxidase (MPO) path-
ways.24 Site-speciﬁc oxidative modiﬁcation of PON-1 by MPO
impairs the enzymes ability to bind with APOA-1 and reduced
MPO could explain the increased PON-1 activity in our
patients.25
We did not demonstrate any differences in cholesterol efﬂux
with either treatment regimen. This suggests that anti-
inﬂammatory therapies have a more pronounced impact on the
vascular properties of HDL than on its efﬂux capacity. These
ﬁndings support previous reports from our group and indicate
that the endothelial function of HDL may be more sensitive to
modiﬁcation than cholesterol efﬂux.6 However, anti-
inﬂammatory treatments including MTX and inﬂiximab have
recently been associated with improved cholesterol efﬂux in
patients with RA, and associated with CV disease in both
healthy and at-risk populations.10 26–28 These differences may
be due to methodological issues in the efﬂux measurement and
their interpretation, and require further investigation.
Our study was not powered to assess the quantitative relation-
ship between HDL function, inﬂammation and disease activity.
This also limited our ability to test for between-treatment differ-
ences in the randomised study design, although combination
therapy demonstrated a clear beneﬁt in the single-blinded study.
However, we have demonstrated that a range of vascular proper-
ties of HDL can be improved with anti-inﬂammatory drug
therapy. HDL function did not return to normal levels following
treatment, and this is likely to be as a result of the residual
levels of inﬂammation even after 2 years treatment (data not
shown).
The ability of anti-inﬂammatory treatments to modify CV risk
remains an intense area of clinical research. Currently, three
anti-inﬂammatory agents are the subject of phase III trials;
MTX (CIRT), Darapladib (SOLID-TMI and STABILITY) and
canakinumab (CANTOS). Recently, both the STABILITY and
SOLID-TMI trials reported that darapladib failed to reduce the
risk of CV death and myocardial infarction in primary and sec-
ondary prevention.29 30 The CIRT and CANTOS trials are due
to report shortly, but our data suggest that monotherapy with
MTX alone may not be sufﬁcient. Inhibition of TNF-α, a broad
immune effector, is more likely to suppress inﬂammation and
may be a better strategy for CV beneﬁt.
This study underlines the need to measure and better under-
stand HDL function. It provides evidence for the use of anti-
inﬂammatory treatments, particularly those modulating the
TNF-α pathway, to restore the beneﬁcial effects of HDL on the
vasculature. Our ﬁndings are of relevance to many recent clin-
ical trials evaluating both HDL elevation and anti-inﬂammatory
therapies with the aim of reducing CV risk.
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